
Display Settings:

Abstract

Full text links

Eur J Surg Oncol. 2009 Aug;35(8):838-43. doi: 10.1016/j.ejso.2008.09.017. Epub 2008 Nov 17.



Survival and recurrence after neo-adjuvant chemotherapy and liver resection for colorectal metastases: a ten year study.

Karanjia ND¹, Lordan JT, Fawcett WJ, Quiney N, Worthington TR.

Author information

Abstract

BACKGROUND: Currently liver resection offers the only potential cure for colorectal liver metastases (CRLM). We prospectively audited the outcome of CRLM treated by a combination of neo-adjuvant chemotherapy and surgery.

METHODS: 283 consecutive patients underwent liver resection for CRLM over 10 years with curative intent. Patients received chemotherapy preoperatively for synchronous and early (< 2 years) metachronous metastases. Univariate and multivariate analyses were used to identify mortality risk factors.

RESULTS: Overall survival at 1, 3 and 5 years was 90%, 59.2% and 46.1%, respectively. Disease free survival at 1, 3 and 5 years was 68.1%, 34.8% and 27.9%, respectively. Operative mortality was 2.1% and morbidity was 23.7%. Patients with macroscopic diaphragm invasion by tumour, CEA > 100 ng/ml, tumour size > 5 cm or cancer involved resection margins (CIRM) had a significantly worse overall survival. Incidence of CIRM and re-resection was 4.9% and 4.5%, respectively.

CONCLUSIONS: Neo-adjuvant chemotherapy followed by liver surgery is associated with improved survival and low CIRM and re-resection rates.

PMID: 19010633 [PubMed - indexed for MEDLINE]

MeSH Terms, Substances

LinkOut - more resources

PubMed Commons

PubMed Commons home

0 comments

How to join PubMed Commons